Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01

Cancer

Volumn 118, Issue 22, 2012, Pages 5614-5622

  Kidwell, Kelley M ^a,b   Yothers, Greg ^a,b   Ganz, Patricia A ^a,c   Land, Stephanie R ^a,b   Ko, Clifford Y ^a,c   Cecchini, Reena S ^a   Kopec, Jacek A ^a,d   Wolmark, Norman ^a,e  

^a NSABP Foundation Inc   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

colon cancer; neurotoxicity; oxaliplatin; randomized clinical trial; stage II III

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL FEATURE; COLON CANCER; CONTROLLED STUDY; DISEASE SEVERITY; EAR DISEASE; FEMALE; FOOT DISEASE; FOOT PAIN; HAND DISEASE; HAND PAIN; HEARING DISORDER; HUMAN; LONGITUDINAL STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROTOXICITY; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN TINGLING; SURVIVAL TIME; TREATMENT OUTCOME; WALKING DIFFICULTY; WEAKNESS;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS;

EID: 84868191145     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27593     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin. 2010; 60: 277-300.
2. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resented colon carcinoma. N Engl J Med. 1990; 322: 352-358.
3. O'Connell MJ, Mailliard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol. 1997; 15: 246-250.
4. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993; 11: 1879-1887.
5. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004; 22: 3408-3419.
6. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005; 23: 8671-8678.
7. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005; 352: 2696-2704.
8. Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project protocol C-06. J Clin Oncol. 2006; 24: 2059-2064.
9. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 2343-2351.
10. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years [abstract]. J Clin Oncol. 2005; 23 (16S). Abstract 3501.
11. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007; 25: 2198-2204.
12. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol. 2009; 27: 3109-3116.
13. Centers for Disease Control and Prevention (CDC). Cancer survivors-United States, 2007. MMWR. 2011; 60: 269-272.
14. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 including survival and subset analyses. J Clin Oncol. 2011; 29: 3768-3774.
15. Kopec JA, Land SR, Cecchini RS, et al. Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin [serial online]. J Support Oncol. 2006; 4: W1-W8. Available at: http://www.supportiveoncology.net/jso/journal/abstracts/0408396.html. Accessed November 29, 2011.
16. Yothers G, O'Connell MJ, Colangelo L, et al. 5-FU and leucovorin (Lv) with or without oxaliplatin (Ox) for adjuvant treatment of stage II and III colon cancer: long-term follow-up of NSABP C-07 with survival analysis [abstract]. Paper presented at: ASCO Gastrointestinal Cancers Symposium; Orlando, FL; January 22-24, 2010. Abstract 401.
17. Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007; 25: 2205-2211.
18. Ganz P, Land SR, Antonio C, et al. Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. J Cancer Surviv. 2009; 3: 137-147.
19. National Cancer Institute (NCI). NCI Cancer Therapy Evaluation Program: Common Toxicity Criteria, Version 2.0. Available at: http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcv20-4-30-992.pdf. Accessed November 29, 2011.
20. Kuroi K, Shimozuma K,. Neurotoxicity of taxanes: symptoms and quality of life assessment. Breast Cancer. 2004; 11: 92-99.
21. Cella D, Peterman A, Hudgens S, et al. Measuring the side effects of taxane therapy in oncology: the Functional Assessment of Cancer Therapy-taxane (FACT-taxane). Cancer. 2003; 98: 822-831.
22. Kunitake H, Zheng P, Yothers G, et al. Routine preventive care and cancer surveillance in long-term survivors of colorectal cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol LTS-01. J Clin Oncol. 2010; 28: 5274-5279.
23. Park SB, Lin CS, Krishnan AV, et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist. 2011; 16: 708-716.
24. Mold JW, Vesely SK, Keyl BA, et al. The prevalence, predictors, and consequences of peripheral sensory neuropathy in older patients. J Am Board Fam Pract. 2004; 17: 309-318.
25. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011; 29: 1465-1471.
26. Park SB, Lin CS-Y, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009; 132: 2712-2723.
27. Boige V, Mendiboure J, Pignon JP, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol. 2010; 28: 2556-2564.
28. Park SB, Lin CS-Y, Krishnan AV, et al. Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. Exp Neurol. 2011; 227: 120-127.
29. Braun MS, Seymour MT,. Molecular markers of chemotherapy toxicity in colorectal cancer. Curr Colorectal Cancer Rep. 2011; 7: 105-111.